Study finds exenatide and oxygen strategies did not improve outcomes for heart surgery patients.

The GLORIOUS trial found that exenatide, a GLP-1 receptor agonist, did not improve outcomes like death, stroke, or organ failure in heart surgery patients. The study, involving about 1,400 patients, also showed no benefit from a liberal or restrictive oxygenation strategy. Despite these neutral results, researchers highlighted the need for further studies to find better methods for improving patient outcomes during and after heart surgery.

November 17, 2024
3 Articles

Further Reading